Noninvasive NAVA Versus Flow-triggered Noninvasive Pressure Support in Pediatric Respiratory Failure
| 追踪信息 | |||
|---|---|---|---|
| 首次提交日期 ICMJE | October 4, 2018 | ||
| 首次发布日期e ICMJE | October 5, 2018 | ||
| 最后更新发布日期 | October 5, 2018 | ||
| 预计研究开始日期 ICMJE | October 3, 2018 | ||
| 预计主要完成日期 | January 2019 (主要结果测量的最终数据收集日期) | ||
| 目前主要观察指标 ICMJE |
Intubation rate[ Time Frame: First 48 hours from PICU admission ] Frequency of intubation between the two treatment |
||
| 原始主要观察测量 ICMJE | 与当前相同 | ||
| 目前的二级观察 ICMJE |
|
||
| 描述性信息 | |||
| 简略标题 ICMJE | Noninvasive NAVA Versus Flow-triggered Noninvasive Pressure Support in Pediatric Respiratory Failure | ||
| 正式标题 ICMJE | Noninvasive Neurally Adjusted Ventilatory Assist Versus Flow-triggered Noninvasive Pressure Support in Pediatric Acute Respiratory Failure: an Observational Study | ||
| 简要概况 | Acute Hypoxemic Respiratory Failure (AHRF) is a leading cause of admission in Pediatric Intensive Care Unit (PICU). Traditional treatment includes endotracheal intubation and mechanical ventilation, that are invasive and not free from risks. Recent experiences from pediatric studies showed that Non-Invasive Pressure Support Ventilation (NIV-PS) has been associated with lower intubation rate, adverse events and mortality compared to mechanical ventilation delivered by an endotracheal tube. Nonetheless, in pediatric ARF, the application of a well-synchronized NIV-PS is technically challenging due to the presence of leaks and the age-specific characteristics of pediatric respiratory pattern (high respiratory rate, short inspiratory/expiratory time and weak inspiratory effort). Consequently, NIV-PS often results in difficult patient-ventilator interaction, with a failure rate up to 43% . Neurally Adjusted Ventilatory Assist (NAVA) is a new form of ventilatory assistance wherein the ventilator applies positive pressure throughout inspiration synchronously and proportionally to the Electrical Diaphragm activity (Edi). Thus, NAVA is not influenced by large leaks around uncuffed endotracheal tubes or noninvasive interfaces. Studies in intubated children found that NAVA improved interaction by reducing asynchronies and optimizing ventilator cycling.Two recent studies showed that the application of Non-Invasive NAVA (NIV-NAVA) in children with ARF is feasible and may reduce asynchronies as compared to NIV-PS. More recently, in a recent RCT of our group, we demonstrated that NIV NAVA in children was associated with lower asynchronies, longer synchronization time between patient and ventilator at lower peak and mean airway pressure. However no data are published to address the question if the better synchronization between patients and ventilator obtained with NIV NAVA could lead to a reduction in intubation rate and PICU outcomes. To address this question, we designed an observational retrospective study aiming to define if early delivered NIV NAVA could reduce intubation rate if compared with traditionally flow-cycled NIV PS in hypoxemic children admitted to PICU. |
||
| 详细说明 | End point Primary end point is the intubation rate between groups. Secondary end points include: days on mechanical ventilation, number o invasive devices, nosocomial infections, PICU and Hospital length of stay and survival at 2-6 months. Study design Single center retrospective study Sample size calculation and statistical analysis According to previous studies, the reported intubation rate in children admitted to PICU with AHRF and treated with conventional flow-cycled NIV-PS is 40%-60%. Considering an alfa -error=0.05 and power=80%, the study would have needed 20 patients in each group to detect a 50% reduction in the primary end point, i.e. the intubation rate. Data distribution are tested with Kolmogorov-Smirnov analysis and analyzed with parametric or non-parametric statistics, according to. Normally distributed variables are expressed as mean (SD) while median and interquartile range are used to report non-normally dsitributed variables. Categorical variables are compared with chi-square or Fisher exact test, as appropriate. A p value <0.05 was considered as significant. Sample size calculation was performed with GPower 3.1.2 software (Kiel University, Germany). Other statistics were performed with SPSS 15.0 (SPSS inc, Chicago, IL, USA) and p<0.05 was considered as statistically significant Study Population All consecutive children with infectious AHRF meeting the pediatric criteria for moderate ARDS definition admitted to PICU between the first January 2015 and first January 2017. Eligible patients received Noninvasive Respiratory Support as a first line respiratory treatment and were divided in two groups: 1) patients receiving flow-cycled NIV-PS as a first line treatment (control group) and b) patients receiving NIV NAVA as a first line treatment (treatment group). Experimental protocol. The routine management of children wth AHRF treated with noninvasive respiratory support did not vary in the study period and included: 1) standard medical therapy including oxygen therapy, antibiotics, steroids, inhaled beta 2 agonists if needed 2) maintaining semirecumbent position 2) sedation provided according to PICU protocol (dexmedetomidine 0.5-0.7mcg/Kg/hour) to maintain a COMFORT score between 17 and 26; To achieve the "best ventilatory assistance" during NIV-PS, the PS level (i.e. the inspiratory pressure support above PEEP) and NAVA gain were set to obtain an expiratory tidal volume 6-9 ml/Kg (while the child was on active inspiration, as shown by a positive inflection on the pressure trace), a reduction in RR and in chest retractions, as reported previous studies. In both trials Positive End-Expiratory Pressure (PEEP) was titrated from 4 to 8 cmH2O (in step of 2 cmH2O) to obtain SaO2> 94% with FiO2 <0.6. During NIV-PS the inspiratory flow-trigger was set at maximum sensitivity level not causing autotriggering. The expiratory cycling-off was adjusted by the attending physicians to obtain the best synchronization, according to flow/pressure tracings. During NIV-NAVA, Edi trigger was set at 0.5 μV above the resting Edi to assist respiratory effort without responding to electrical noise. NIV NAVA was delivered with ServoI ventilator equipped with Edi module (Maquet, Solna, Sweden). NIV PS flow cycled was delivered with different ventilators equipped with a specific module for lueaks compesaton and pediatric /neonatal inspiratory trigger module (ServoI Maquet Solna Sweden; Evita VN 500 Lubeck Germany). Pediatric Interfaces includes full face masks Performax, in different size (neonatal and pediatric) (Respironics, Murrysville). | ||
| 研究类型 ICMJE | Observational | ||
| 研究阶段 | |||
| 研究设计 ICMJE | 分配: 干预模型: 干预模型描述: 盲法: Observational 盲法描述: 主要目的: |
||
| 适用条件 ICMJE | |||
| 干预项目 ICMJE |
|
||
| 研究工具 |
|
||
| 招募信息 | |||
| 招募状态 ICMJE | Enrolling by invitation | ||
| 预计入组 ICMJE |
60 | ||
| 原始预计入组 ICMJE | 与当前相同 | ||
| 预计研究完成日期 | February 2019 | ||
| 预计主要完成日期 | January 2019 (主要结果测量的最终数据收集日期) | ||
| 合格标准 ICMJE | Inclusion Criteria Age > 1month and < 5 years; paO2: FIO2 <300 with oxygen mask (FiO2=0.4) for 15 minutes Respiratory Rate (RR)>2SD according to age Bilateral Chest X ray infiltrates Absence of cardiopathy diagnosed by ecochardiography . Exclusion Criteria: Emergency need for intubation Glasgow Coma Scale <12 pH<7.25 Cough reflex impairment Upper-airway obstruction Hemodynamic instability (need for vasopressor or inotropes) Evidence of pneumothorax on lung echo or chest x ray Esophageal surgery, neuromuscular, mitochondrial, metabolic or chromosomal diseases with baby hypotonia and lesions of medulla. Were excluded even patients whose parents denied the consent to manage personal data at admission and patient lacking data on medical charts report | ||
| 性别 |
|
||
| 年龄 | 最小年龄：N/A ，最大年龄：N/A | ||
| 接受健康的志愿者 | 没有 | ||
| 可入组国家 ICMJE | Italy | ||
| 管理信息 | 数据检测委员会 | No | |
| 研究涉及美国FDA监管的产品 |
研究美国FDA监管的药品: No 研究涉及美国FDA监管的设备产品: No |
||
| IPD 共享声明 |
|
||
| 责任方 | ， | ||
| 研究赞助商 ICMJE | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | ||
| 合作者 ICMJE | |||
| 研究员 ICMJE |
|
||
| PRS 账户 | |||
| 验证日期 | October 2018 | ||
|
ICMJE 国际医学期刊编辑委员会和 世界卫生组织 ICTRP 要求的元素 |
|||
京公网安备 11010102003638号